POM-V Prescription Required Companion Animal

Clindabactin 55 mg Chewable Tablets for Dogs and Cats

Active ingredient: Clindamycin

Form

Chewable

Species

Cats Dogs

Manufacturer

Dechra Regulatory B.V.

VMD MA No.

50406/4004

What it's used for

Streptococcus spp. (except ), Bacteroides spp., Fusobacterium necrophorum, and Clostridium perfringens susceptible to clindamycin. For the treatment of sup...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Clindamycin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Clindabactin 55 mg Chewable Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Streptococcus spp. (except ), Bacteroides spp.,
Fusobacterium necrophorum, and Clostridium perfringens susceptible to clindamycin.
For the treatment of superficial pyoderma associated with Staphylococcus
pseudintermedius
For the treatment of osteomyelitis, caused by susceptible to
clindamycin.
AN: 00690/2024, 00691/2024, 03555/2024 & 03558/2024
Cats:
For the treatment of infected wounds and abscesses, and oral cavity infections
including periodontal disease, caused by bacteria susceptible to clindamycin.

1. For the treatment of infected wounds and abscesses, and oral cavity infections
including periodontal disease in dogs and cats, administer either:
• 5.5 mg clindamycin/kg bodyweight every 12 hours for 7-10 days, or
• 11 mg clindamycin/kg bodyweight every 24 hours for 7-10 days
If no clinical response is seen within 4 days, redetermine the diagnosis.
2. For the treatment of superficial pyoderma in dogs, administer either:
• 5.5 mg clindamycin/kg bodyweight every 12 hours, or
• 11 mg clindamycin/kg bodyweight every 24 hours
Therapy of canine superficial pyoderma is usually recommended for 21 days, with
shortening or extension of therapy based on clinical judgement.
3. For the treatment of osteomyelitis in dogs, administer:
• 11 mg clindamycin/kg bodyweight every 12 hours for a minimum of 28 days
If no clinical response is seen within 14 days, the treatment should be stopped and
the diagnosis redetermined.
To ensure a correct dosage, bodyweight should be determined as accurately as
possible to avoid under-dosing.
Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing.
AN: 00690/2024, 00691/2024, 03555/2024 & 03558/2024
Place the tablet on a flat surface, with its scored side facing up and the convex
(rounded) side facing the surface.
2 equal parts: press down with your thumbs on both sides of the tablet.
4 equal parts: press down with your thumb in the middle of the tablet.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients or to lincomycin. Do not administer to rabbits, hamsters, guinea pigs,
chinchillas, horses and ruminants, because ingestion of clindamycin by these species
can cause severe gastro-intestinal disturbance which may result in death.

Dogs, cats:
Uncommon
(1 to 10 animals / 1,000
animals
treated):
Vomiting, diarrhoea, disorder of gastrointestinal
flora
a
a
Clindamycin causes overgrowth of non-sensitive organisms such as resistant
clostridia and yeasts. In cases of superinfection, appropriate measures must be
taken according to the clinical situation.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
The chewable tablets are flavoured. In order to avoid any accidental ingestion, store
tablets out of reach of the animals.
Use of the veterinary medicinal product should be based on susceptibility testing of
the target bacteria isolated from the animal. If this is not possible, therapy should be
based on local epidemiological information and knowledge of susceptibility of the
target pathogens at local/regional level.
Use of the veterinary medicinal product should be in accordance with official, national
and regional antimicrobial policies.
Use of the veterinary medicinal product deviating from the instructions given in the
SPC may increase the prevalence of bacteria resistant to clindamycin and may
decrease the effectiveness of treatment with lincomycin or macrolide antibacterials
due to the potential for cross-resistance.
Cross-resistance has been demonstrated among lincosamides (including
clindamycin), erythromycin and other macrolides.
In some cases (localised or mild lesions; to prevent recurrence), superficial pyoderma
can be treated topically. The need for and duration of systemic antimicrobial
treatment should be based on careful consideration of the individual case.
During prolonged therapy of one month or greater, periodic liver and kidney function
tests and blood counts should be performed.
Animals with severe renal and/or very severe hepatic disturbances accompanied by
severe metabolic aberrations should be dosed with caution and should be monitored
by serum examination during high-dose clindamycin therapy.
The use of the veterinary medicinal product is not recommended in neonates.
AN: 00690/2024, 00691/2024, 03555/2024 & 03558/2024
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Lincosamides (lincomycin, clindamycin, pirlimycin) may cause hypersensitivity
(allergy) reactions. People with known hypersensitivity to lincosamides should avoid
contact with the veterinary medicinal product.
Wash hands after handling tablets.
Accidental ingestion may result in gastro-intestinal effects such as abdominal pain
and diarrhoea. Care should be taken to avoid accidental ingestion.
In order to reduce the risk of accidental ingestion by children, do not take the tablets
out of the blister until ready to administer to the animal. Return part-used tablets into
the blister and carton and use at the subsequent administration.
In case of accidental ingestion, particularly by children, seek medical advice
immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

Clindamycin hydrochloride has been shown to have neuromuscular blocking
properties that may enhance the action of other neuromuscular blocking agents. The
veterinary medicinal product should be used with caution in animals receiving such
agents.
Aluminium salts and hydroxides, kaolin and aluminium-magnesium-silicat complex
may reduce the absorption of lincosamides. These digestive substances should be
administered at least 2 hours before clindamycin.
Clindamycin should not be used concomitantly with or immediately after erythromycin
or other macrolides to prevent macrolide-induced resistance to clindamycin.
Clindamycin may reduce plasma levels of cyclosporine with a risk of lack of activity.
During the simultaneous use of clindamycin and aminoglycosides (e.g.gentamicin),
the risk of adverse interactions (acute renal failure) cannot be excluded.
Clindamycin should not be used concomitantly with chloramphenicol or macrolides as
they antagonise each other at their site of action at the 50S ribosomal sub-unit.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.